Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 531Gastro-enteropancreatic neuroendocrine tumor 58Carcinoid Tumor 58Neoplasms 49Carcinoma, Neuroendocrine 44Pancreatic Neoplasms 36Adenoma, Islet Cell 33Neoplasm Metastasis 28Pheochromocytoma 25Colorectal Neoplasms 24Paraganglioma 23Stomach Neoplasms 21Breast Neoplasms 21Prostatic Neoplasms 20Lung Neoplasms 20Carcinoma, Hepatocellular 20Sarcoma 19Carcinoma 19Thyroid Neoplasms 18Gastrointestinal Neoplasms 18Neuroblastoma 15Cholangiocarcinoma 14Carcinoma, Renal Cell 14Small Cell Lung Carcinoma 13Melanoma 13Esophageal Neoplasms 13Serotonin Syndrome 12Colonic Neoplasms 12Brain Neoplasms 11Adenocarcinoma 11

Interventions

lutetium Lu 177 dotatate 1X-Rays 1Specimen Handling 1Photons 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Lung Neuroendocrine Tumor × NET × Clear all
NCT04665739 2026-05-13

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
EndocrineNET

Advanced Lung Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡